Senti Biosciences Holdings (SNTI) Non-Current Assets (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Non-Current Assets of $27.9 million for Q4 2025, down 28.11% year-over-year from $38.9 million in Q4 2024, and down 19.05% quarter-over-quarter from $34.5 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Non-Current Assets (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Non-Current Assets history runs 5 years deep, the most recent figure standing at $27.9 million for Q4 2025.
- In Q4 2025, Non-Current Assets fell 28.11% year-over-year to $27.9 million; the TTM figure through Dec 2025 stood at $136.1 million (down 19.16% YoY), while the FY2025 annual figure was $27.9 million, down 28.11% from the prior year.
- Non-Current Assets for Q4 2025 stood at $27.9 million, down from $34.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $230.1 million in Q1 2022, with the low at $27.9 million in Q4 2025.
- The 5-year median for Non-Current Assets is $48.3 million (2023), against an average of $78.9 million.
- Peak annual rise in Non-Current Assets reached 114.23% in 2022, while the deepest fall reached 74.59% in 2022.
- Senti Biosciences Holdings' Non-Current Assets stood at $36.5 million in 2021, then soared by 114.23% to $78.2 million in 2022, then slumped by 38.27% to $48.3 million in 2023, then slipped by 19.48% to $38.9 million in 2024, then dropped by 28.11% to $27.9 million in 2025.
- Business Quant data shows SNTI's Non-Current Assets at $27.9 million in Q4 2025, $34.5 million in Q3 2025, and $36.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 18.06 Bn |
| 10 | Senti Biosciences Holdings | 13.24 Mn | 13.24 Mn | - | 20.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 27.95 Mn |
| Sep 30, 2025 | 34.53 Mn |
| Jun 30, 2025 | 36.02 Mn |
| Mar 31, 2025 | 37.57 Mn |
| Dec 31, 2024 | 38.88 Mn |
| Sep 30, 2024 | 40.34 Mn |
| Jun 30, 2024 | 42.57 Mn |
| Mar 31, 2024 | 46.52 Mn |
| Dec 31, 2023 | 48.28 Mn |
| Sep 30, 2023 | 52.76 Mn |
| Jun 30, 2023 | 80.14 Mn |
| Mar 31, 2023 | 80.91 Mn |
| Dec 31, 2022 | 78.21 Mn |
| Sep 30, 2022 | 69.68 Mn |
| Jun 30, 2022 | 58.44 Mn |
| Mar 31, 2022 | 230.09 Mn |
| Dec 31, 2021 | 36.51 Mn |
| Sep 30, 2021 | 230.00 Mn |
| Jun 30, 2021 | 230.00 Mn |